Randomised Controlled Trial Of Virtual Reality Therapy After Stroke
Funder
National Health and Medical Research Council
Funding Amount
$452,264.00
Summary
Stroke is the second largest cause of disability in Australia. There is no cure, so patients must rely on therapy to restore movement. We want to make rehabilitation more effective. This study compares virtual reality game therapy (using the Nintendo Wii) to current best practice (constraint therapy). We anticipate patients will improve more with Wii therapy. Because it is fun, patients will enjoy therapy and spend longer training resulting in a greater recovery and better movement ability.
A Randomised Trial Of Constraint Induced Movement Therapy And Botulinum Toxin A In Children With Congenital Hemiplegia.
Funder
National Health and Medical Research Council
Funding Amount
$399,995.00
Summary
Congenital hemiplegia occurs in over 1 million children under 21 years of age in the industrialized world. It is the most common type of cerebral palsy, accounting for 36 percent of children diagnosed with this lifelong condition. We intend to determine if a promising new treatment approach is effective in providing a superior and lasting benefit, compared to conventional techniques. Children with hemiplegia usually have the intellectual capacity to attend normal school; however the impaired arm ....Congenital hemiplegia occurs in over 1 million children under 21 years of age in the industrialized world. It is the most common type of cerebral palsy, accounting for 36 percent of children diagnosed with this lifelong condition. We intend to determine if a promising new treatment approach is effective in providing a superior and lasting benefit, compared to conventional techniques. Children with hemiplegia usually have the intellectual capacity to attend normal school; however the impaired arm reduces independence in activities of daily living and can compromise their ability to participate in educational, leisure and vocational roles. Previously we have shown that a program of upper limb rehabilitation in children with spasticity was effective in improving participation and quality of life. We have also shown that rehabilitation combined with Botulinum toxin A (Botox) can further improve functional activity. We believe that a new method of therapy, that has been used effectively in Adults with stroke, called Constraint Induced Movement Therapy (CIMT) may also be beneficial in the treatment of children with congenital hemiplegia. In CIMT, the unimpaired arm is constrained in a glove to promote use of the impaired arm (hemiplegic arm). We predict that, combined with the Botox treatment, CIMT will provide a superior and longer lasting benefit compared to standard rehabilitation combined with Botox. The primary aim of our study is to test this hypothesis in a controlled trial. A secondary aim is to further our understanding of the central neurovascular mechanisms underlying changes in upper limb function. To achieve this, we will use Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS) to measure central activation in the parts of the brain controlling movement. Improving our understanding of the mechanisms involved in this condition is an essential next step towards providing a more effective and long lasting treatment.Read moreRead less
Generation Of Induced Pluripotent Stem (iPS) Cells And Their Potential Use In Periodontal Regeneration
Funder
National Health and Medical Research Council
Funding Amount
$798,350.00
Summary
Dental diseases affecting the gums (periodontal diseases) are extremely prevalent. The effects of periodontal disease can be particularly severe as loss of support for the teeth leads to loose teeth and severely compromised chewing function. If left untreated, the associated loss of function may necessitate extraction of the teeth. We propose to generate induced pluripotent stem cells from gums and explore whether they can be used to restore periodontal tissues damaged by periodontal disease.
Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil. Eosinophils are evaluated in sputum samples from the airways and are commonly reported in increased levels from people with asthma. Recent work has identified that some people have symptoms of asthma but their eosinophil levels remain normal. Those with non-eosinophilic asthmatics may account for up to 50% of all asthma reported. Our study will ....Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil. Eosinophils are evaluated in sputum samples from the airways and are commonly reported in increased levels from people with asthma. Recent work has identified that some people have symptoms of asthma but their eosinophil levels remain normal. Those with non-eosinophilic asthmatics may account for up to 50% of all asthma reported. Our study will investigate the cells present in the sputum of people that have non-eosinophilic asthma. It has been speculated that neutrophils (another cell causing inflammation in the lungs) may be responsible. Neutrophils are known to cause inflammation and release many chemical mediators, which are capable of destroying lung tissue. We will focus on the neutrophil and the chemicals that cause neutrophils to move into the lungs and then destroy tissue. By comparing the levels of neutrophils and its mediators between the eosinophilic and non-eosinophilic asthma populations it may be possible to understand the mechanism behind non-eosinophilic asthma. Current asthma treatments-preventers focus essentially on controlling the inflammation caused by eosinophils. By understanding what is causing the inflammation in people without eosinophils in their sputum, we can begin to investigate and design new treatments. One possible treatment is the use of macrolide antibiotics. These medicines have been shown to be useful in reducing inflammation in other chronic inflammatory diseases. We plan to investigate the usefulness of a macrolide antibiotic (erythromycin) in reducing inflammation in non-eosinophilic asthma by a randomised-controlled trial. Armed with more information about non-eosinophilic asthma we will be able to more effectively diagnose and treat this group in the community.Read moreRead less
Evaluation Of A Novel Antiosteolytic Agent: Potential In Breast-to-bone Metastasis And Mechanism Of Action
Funder
National Health and Medical Research Council
Funding Amount
$352,583.00
Summary
In breast cancer the spread of cancer (metastasis) to bone occurs frequently and causes significant problems including pain, fracture, immobility and paralysis. We have recently discovered that a drug, widely used in Japan and Korea for skin disorders, inhibits breast cancer growth in bone using animal model systems of this disease. This is a very exciting and novel finding. We will further investigate the potential of this drug and identify precisely how it works at the molecular level.
Strengthening Functional Connectivity In The Ageing Brain.
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Age-related deficits in the ability to perform meaningful, voluntary movements markedly increase the likelihood of experiencing falls, a major cause of injury among older adults. Using advanced neurophysiological techniques, this project will (1) define the role of functional connectivity decline in age-related movement deficits and (2) gain a mechanistic understanding of improvements in voluntary movement control through a promising intervention for reversing age-related functional decline.
Therapeutic Induction Of Dytrophin-positive Revertant Fibres In The Mdx Mouse
Funder
National Health and Medical Research Council
Funding Amount
$454,825.00
Summary
Revertant fibres are low-abundance, dystrophin-positive fibres found in muscle of DMD patients and animal models. These fibres appear to have a selective advantage over dystrophin negative fibres, as they accumulate with age. Characterisation of dystrophin mRNA has identified in-frame transcripts missing multiple exons, which either exclude a nonsense mutation or restore the reading frame around a deletion. We have designed antisense oligonucleotides (AOs) to bind regions flanking the exon conta ....Revertant fibres are low-abundance, dystrophin-positive fibres found in muscle of DMD patients and animal models. These fibres appear to have a selective advantage over dystrophin negative fibres, as they accumulate with age. Characterisation of dystrophin mRNA has identified in-frame transcripts missing multiple exons, which either exclude a nonsense mutation or restore the reading frame around a deletion. We have designed antisense oligonucleotides (AOs) to bind regions flanking the exon containing the dystrophin mutation in the mdx mouse. The AOs interfere with processing of the pre-mRNA to exclude the mutation and allow a slightly shortened dystrophin to be synthesised. The use of AOs to modify RNA processing allows the gene to function under the control of natural regulatory elements. We have shown that AOs can induce dystrophin expression and improve strength in dystrophic (mdx) mouse hindlimb muscles. We aim to improve upon these results by using AOs to block splice sites flanking consecutive exons, in order to induce dystrophin which mimics that of revertant fibres. As most revertant transcripts are missing multiple exons, we believe that the functional capacity of AO-induced dystrophin can be improved upon by removing multiple exons. An mdx mouse skeletal muscle cell line is used for evaluation AOs. However, in order to determine the efficacy of the induced dystrophin in cardiac and skeletal muscle, experiments must be performed on mice. Previous work, in vitro and in muscles of mdx mice have validated this approach. Combinations of AOs which show promise will be delivered by a) intravascular injection b) intraperitoneal injection in mdx mice. The efficacy of the treatment will be assessed by both continual and end point analysis, which includes physiological, clinical, molecular and histological testing. Particular attention will be directed to the well-being of the mice and any adverse side effects which may occur.Read moreRead less
Molecular Characterisation Of TRAIL-regulated Signal Transduction Pathways And Their Role In The Development, Persistence, And Exacerbation Of Allergic Airways Disease
Funder
National Health and Medical Research Council
Funding Amount
$637,035.00
Summary
Molecules that promote the development, persistence, and exacerbation of asthma are only poorly defined. We have discovered a novel signalling pathway that is activated in the airway wall during asthma. Blocking a molecule that activates this pathway ameliorated asthma in mice. We now want to identify all the important components of this pathway and therapeutically modulate them to prevent the development, persistence, and exacerbation of asthma.
The Role Of The Osteoblast In Mediating Glucocorticoid-Induced Metabolic Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$825,254.00
Summary
Glucocorticoids (GC) exceed most other drugs in terms of numbers of patients treated and indications. Preventing or attenuating the deleterious effects of GC on fuel metabolism is therefore of great clinical significance. Our studies will create new knowledge regarding the mechanisms of GC-induced diabetes and osteoporosis, and will contribute to the development of new approaches that are essential to tackle the pressing medical problem of GC-induced disease.
NaviGAIT: New Software To Simplify Interpretation Of Gait Analysis Data
Funder
National Health and Medical Research Council
Funding Amount
$179,905.00
Summary
NaviGAIT is a new software package to support interpretation of gait analysis data. It is based upon Gait Profiling, a new technique to reduce the complexity of such data. At present data intepretation is restricted to a few expert clinicians. The new software will allow non-expert clinicians to interpret data and hence make gait analysis more accessible, cheaper and more clincally useful. A module of NaviGAIT specifically for children with cerebral palsy will be the first to be developed.